Avalyn Pharma
AVLN----
Q2 FY2026 EarningsQ2 FY26 reported a wider-than-expected net loss of $28.9M vs. $28.2M consensus. GAAP EPS was -$0.91 (calculated) vs. -$0.77 expected, driven by higher R&D and G&A scaling following the May 2026 IPO. The MIST Phase 2b trial for AP01 completed enrollment with 398 patients, exceeding targets, while a robust cash balance of $413.5M extends the runway into 2029.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Avalyn Pharma(AVLN) the EBIT is -31.29 M (--%), Miss estimate;the EPS is -0.98 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.03B--
-0.03B--
-0.00B--%
EPSMiss expectations
-0.98--
-0.7733--
-0.2067--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf